Objective To examine the effectiveness of the health system response to the challenge of diabetes across different settings and explore the inequalities in diabetes care that are attributable to socioeconomic factors.
Five strategies can help reduce the burden of diabetes at the population level: (i) case prevention through reductions in modifiable risk factors such as obesity; (ii) screening coupled with pharmacological or lifestyle interventions targeting individuals with pre-diabetes 9, 10 ; (iii) improved diagnosis and control of blood glucose among individuals with diabetes [11] [12] [13] ; (iv) improved management of microvascular complications, including renal disease, retinopathy, diabetic foot and other neuropathies 14, 15 ; and (v) improved management of associated cardiovascular risks. 13, 16 It is essential to understand how well health systems are performing in terms of these five strategies and the role of health system and individual attributes such as physical access, financial access, provider quality and patient education and motivation.
While diabetes care under specific providers is extensively examined in the literature, [17] [18] [19] there is only one previous comparative analysis of how health systems overall are responding to diabetes. 7 In this paper we expand the range of comparisons by analysing in a consistent way surveys conducted in three developed and four developing settings. We focus the analysis on the two strategies for which data are available: (i)diagnosis and control of blood glucose and (ii) the management of arterial blood pressure and serum cholesterol in individuals with diabetes. We explore the relationship between socio-economic status, financial access to diabetes care and place of residence with effective management of diabetes.
Methods
Our selection of countries was opportunistic. We searched extensively for nationally representative health examination surveys that included measurements of fasting plasma glucose or glycosylated haemoglobin or haemoglobin A1c (HbA1c) as well as arterial blood pressure and serum cholesterol. We downloaded publicly available data sets from the United States of America, England and Scotland. For other countries we requested data and collaboration on this project from the institution that conducted the survey and were able to include surveys from Colombia, the Islamic Republic of Iran, Mexico and Thailand. Table 1 presents the characteristics of each survey. For all surveys except the one conducted in the Islamic Republic of Iran, sampling weights were available and were taken into account in the analysis. Table 2 summarizes the definitions, diagnostic parameters and treatment targets for all the conditions under study. We followed the International Diabetes Federation (IDF) guidelines 26 for diagnosis and treatment values in all cases except for serum cholesterol, for which we used the guidelines of the National Institute for
Health and Clinical Excellence (NICE). 27 Individuals with diabetes were categorized into four mutually exclusive groups: (i) undiagnosed, (ii) diagnosed but untreated, (iii) treated but not controlled (not meeting treatment targets), and (iv) treated and controlled (meeting treatment targets) for blood glucose, blood pressure and serum cholesterol. Our analysis was limited to medical treatment as lifestyle interventions, such as dietary changes, are not measured consistently in the household surveys.
Analysis of determinants
We used logistic regression to explore the determinants of being diagnosed, treated and controlled among individuals with diabetes, separately for each survey. We examined the determinants of having been previously diagnosed by a physician and, among those previously diagnosed, we explored the determinants of having been effectively treated for all identified conditions. We also performed a regression to identify the determinants of meeting treatment targets for blood glucose (Appendix A, available at:
http://www.healthmetricsandevaluation.org/files/2010/diabetes_comparative_analysis/Webapp endix_1.pdf). We controlled for the following determinants: age and sex of the respondent, urban or rural residence, income or wealth quintile, insurance status, and educational level. For Colombia and Mexico we created a household wealth index and divided households into quintiles. For Thailand and the United States, the surveys included information on self-reported income and we divided individuals into income quintiles. In the Islamic Republic of Iran, the survey questionnaire did not include information on income or assets.
In the United States, the survey inquired whether the respondent had or did not have insurance. For
Mexico we used three insurance status categories: (i) uninsured; (ii) insured through the informal sector (Seguro Popular) and (iii) insured through the formal or private sector. For Colombia we used three categories: (i) uninsured; (ii) insured through the informal sector (régimen subsidiado) and (iii) insured through the formal sector (régimen contributivo) or through a special social security fund for the military, the police, teachers and public oil company employees (régimen especial). Insurance status was not available in Thailand or the Islamic Republic of Iran.
All analyses were run using STATA version 11 (StataCorp. LP, College Station, USA).
Results
Fig . 1 shows the age-standardized prevalence and rates of diagnosis of diabetes and the rates of treatment and effective control of blood glucose. Mexico stands out for its high prevalence of the disease, with 24% of males Coverage of treatment with medication for control of blood glucose is higher in developed countries, but low overall, especially in younger people (Fig. 1) . The highest treatment rates were found the United States. In
Colombia, Thailand and the Islamic Republic of Iran the majority of individuals with diabetes were not using medication for blood glucose control. The highest proportion of diagnosed but untreated individuals was found among Colombian women, at 12%.
In all surveys only a small fraction of individuals with diabetes met treatment targets. The United States was the best performer, with about 26% of individuals with diabetes meeting treatment targets. In Colombia, 27% of men and 24% of women were meeting the targets, while England and Scotland were among the worst performers. While the proportion of diabetic individuals who were on treatment was low in Colombia, that country appeared to be more effective than others at reaching treatment targets. countries where more than half of men with diabetes and arterial hypertension had never been diagnosed.
Treatment rates for arterial hypertension followed a similar pattern and were higher in the more developed countries. The highest proportion of individuals with diabetes and hypertension who were meeting treatment targets for hypertension was seen in the United States (38% for men and 25% for women), while in all other surveys fewer than 15% of individuals with diabetes were meeting treatment targets for blood pressure.
The prevalence of hypercholesterolaemia among individuals with diabetes was similarly high; it was above 55% in all surveys except in Mexico, where it was only about 35% (Fig. 3) . Rates of diagnosis are very proportions were meeting treatment targets when compared to those on treatment for hyperglycaemia or hypertension. Fig. 4 depicts how well countries perform overall in managing individuals with diabetes. Effective management was defined in terms of the proportion of individuals with diabetes who were receiving the treatment they required and who were meeting treatment targets for blood glucose, blood pressure and serum cholesterol. Across all surveys, only a small proportion of individuals with diabetes had achieved treatment targets for all three conditions. Within this set of surveys, the United States had the highest rates of effective management, at 13% for men and 6% for women. Ineffective management was assessed in terms of the proportion of individuals who were receiving required treatment for all the conditions they had but who were not meeting treatment targets. A striking finding, shown in Fig. 4 , was the enormous proportion of individuals with diabetes who were undiagnosed or who had been diagnosed but were not being treated for hyperglycaemia, arterial hypertension or hypercholesterolaemia, individually or in combination. It was highest in Thailand, where 88% of the men and 85% of women were lacking management, largely on account of the low rates of diagnosis of hypercholesterolaemia. The United States had the lowest proportion of individuals who were not being managed, but even there more than 40% of men and women with diabetes were undiagnosed or had been diagnosed but were not being treated for one or more conditions. There is substantial room for improvement in the management of diabetes and its associated cardiovascular risks.
Surprisingly, wealth was not significantly associated with the probability of being diagnosed with diabetes (Table 3) anywhere except in Thailand, where the poorest quintile had significantly lower odds of being diagnosed than the richest quintile. In Thailand, individuals with a higher educational level also had significantly higher odds of being diagnosed. In the Islamic Republic of Iran and Thailand, living in an urban location was associated with significantly higher odds of being diagnosed than living in a rural location, but it was not a significant determinant in other surveys. In the United States, Mexico and Colombia, where data were available, insurance status was a strong and significant predictor of diagnosis.
Finally, Table 3 explores the determinants of being on treatment and meeting treatment targets for all existing cardiovascular risks. Once diagnosed, males were less likely to be effectively managed than females in the Islamic Republic of Iran and Mexico, but in Thailand they were more likely to be. In Thailand, the two lowest income quintiles were less likely to be effectively managed, but surprisingly, in other surveys income Publication: Bulletin of the World Health Organization; Type: Research Article ID: BLT.10.080820
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was not a significant determinant of effective management. Similarly, a higher educational level was associated with a higher probability of meeting treatment targets in Colombia but not in other countries. Finally, insured individuals in the United States were almost twice (P < 0.05) as likely to be effectively managed as those without insurance, but insurance status was not associated with effective management in Colombia or Mexico.
It is also important to note that in England and Scotland none of the socio-economic determinants were significantly associated with higher rates of diagnosis or effective treatment.
Discussion
In this paper we present a unique comparative picture of diabetes mellitus management based on an analysis of nationally representative surveys from seven countries, three of them developed and four in development. The overall finding was that a substantial proportion of individuals with diabetes remain undiagnosed and untreated and, perhaps more worryingly, that the percentage of individuals reaching International Diabetes Federation treatment goals for blood glucose, blood pressure and serum cholesterol is very low, ranging from 1% to 12%.
These low rates of diagnosis, treatment and control reflect many lost opportunities for reducing the growing global burden of diabetes.
Once individuals are diagnosed, they are highly likely to be treated with medication, both in developed and in developing countries. Information on the management of hyperglycaemia with lifestyle interventions such as diet is not available. Nevertheless, in all countries more than 70% of individuals with diabetes were not reaching the blood glucose treatment targets set by the International Diabetes Federation and there was considerable variation across the seven surveys. While diagnostic criteria were largely consistent across national guidelines, there was less agreement on the treatment targets for blood glucose (Table 4) , which may partly explain the wide variation in control rates. More recent evidence on the most appropriate treatment targets for blood glucose control 34 further complicates the process of arriving at national and international treatment guidelines that are consistent, acceptable and implemented by national health-care providers and individuals with diabetes. Successful blood glucose management is clearly the result of a complex interplay between physician behaviour and patient adherence to treatment.
One of the keys to the effective management of individuals with diabetes is the treatment of associated cardiovascular risks. 13, 16 Our analysis showed that 28% to 78% of individuals with diabetes who were also hypertensive were being treated or had attained therapeutic control targets. Much greater variation was seen in the treatment of hypercholesterolaemia, with especially low rates of diagnosis and treatment in Thailand.
Control rates for blood pressure and serum cholesterol were much higher than for blood glucose, perhaps because of the high efficacy and minimal side effects of the drugs used to lower blood pressure and serum At least three strategies can be employed to improve the management of diabetes in the short-term. First, efforts to standardize and track the care of patients with diabetes do not appear to have had a major impact to date. Hence, greater effort in this area and clear targets for physicians and patients are needed. Second, offering incentives to providers and patients is a new but promising approach, although it calls for further experimentation and evaluation. These incentives should ideally be related to blood glucose outcomes rather than process measures. The experience of the United Kingdom with providing incentives to physicians to improve the quality of care and disease management will be a source of useful lessons for other countries.
Third, there appears to be an urgent need for technological innovation in the care of diabetes. The poor performance noted, for example, in meeting blood glucose control targets may be strongly related to the narrow window between ideal and excessively low blood glucose levels. Innovations in blood glucose monitoring and drug delivery could increase the proportion of diabetic individuals who remain within an optimal blood glucose range. Clearly, diabetes management has not been successful at the population level and both policy and research need to be strengthened in the future.
In most countries, income, wealth and education were not significantly associated with diagnosis, treatment and control rates. This is an encouraging finding, especially given the large socio-economic inequalities seen in many health outcomes. In Thailand, however, low income and low educational level were significantly associated with lower rates of diabetes diagnosis and effective management, and with the diagnosis and treatment of arterial hypertension and hypercholesterolaemia. 36 These findings suggest a clear need for better strategies targeting the poor in Thailand.
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More intriguing still is the finding that health insurance status is an important predictor of diagnosis and treatment. This underscores the fact that for those who require diagnosis and chronic management, financial access to care is a critical concern. This is particularly evident in the United States. The fact that Mexico has succeeded in expanding financial access to services through a public insurance scheme highlights the interplay between financial access and disease management. Even though Seguro Popular had only existed for two years when the Mexican survey was conducted, individuals with diabetes who were covered by Seguro Popular had been diagnosed at significantly higher rates than those who were uninsured, and at rates comparable to those whether there are differences when diabetes is diagnosed based on fasting plasma glucose versus HbA1c, and as to whether the method used to measure HbA1c is the same across surveys or not. In four of the surveys used in this analysis, fasting plasma glucose was measured, while HbA1c was measured in the other three. Recent literature, however, provides strong evidence that an HbA1c level of 6.5% is equivalent to a fasting plasma glucose level of 126 milligrams (mg) per decilitre (dl). 38 Third, individuals in the sample for whom all three physical examination measures were available were fewer than those for which blood glucose levels were available, and the difference between the two groups varied across countries. Thus, our estimates may have been subject to selection bias. Fourth, much of this analysis relied on self-reported diagnosis and treatment obtained from population surveys, and the limitations of self-reported data are known. It is also impossible to ascertain the reasons for not being on medication or for not reaching treatment targets, and it is possible that poor patience adherence is playing a part. Fifth, the number of individuals with diabetes in the surveys inquiring about diet and physical activity, and this limited our ability to monitor the uptake of these interventions at the population level.
Based on this comparison of how well seven countries are performing in terms of population-level management of diabetes, hypertension and hypercholesterolaemia we make several recommendations. First, since the prevalence of diabetes is increasing worldwide and particularly in developing countries, it is critical to track diabetes care at the population level and to focus on actual outcomes, rather than on the process of care. It is also critical to study other countries with larger numbers of individuals with diabetes, such as India and Self-reported diagnosis of hypertension and self-reported current use of medication for hypertension and systolic blood pressure < 130 mmHg Undiagnosed
No self-reported diagnosis of hypercholesterolaemia and total serum cholesterol  5.0 mmol/l Diagnosed and untreated Self-reported diagnosis of hypercholesterolaemia and no self-reported current use of medication for hypercholesterolaemia and total serum cholesterol  5.0 mmol/l Diagnosed, treated, uncontrolled Self-reported diagnosis of hypercholesterolaemia and self-reported current use of medication for cholesterol and total serum cholesterol  5.0 mmol/l Diagnosed, treated, controlled Self-reported diagnosis of hypercholesterolaemia and self-reported current use of medication for hypercholesterolaemia and total serum cholesterol < 5.0 mmol/l Diagnosed, uncontrolled Individual has diabetes and is either "undiagnosed" or "diagnosed and untreated" for diabetes, hypercholesterolaemia, or hypertension Ineffective management of one or more conditions
Individual has diabetes and is currently taking all necessary medication, but "diagnosed, treated, and uncontrolled" for one or more condition
Comprehensive management
Effective management of all conditions
Individual has diabetes and is "diagnosed, treated, and controlled" for all existing conditions FPG, fasting plasma glucose; HbA1c, glycosylated haemoglobin; mmHg, millilitres of mercury; mmol/l, millimoles per litre.
a Colombia only.
b Islamic Republic of Iran only.
Source: Based on data from nationally representative health examination surveys. 
Diagnosed, Untreated Undiagnosed Fig. 3 . Prevalence, diagnosis and treatment rates for hypercholesterolaemia a among adults in seven-country study of the management of diabetes and associated cardiovascular risk factors F, female; Iran, United Republic of Iran; M, male; US, United States.
a Individuals with hypercholesterolaemia are assigned to one of four groups: (i) undiagnosed, (ii) diagnosed but not on treatment, (iii) diagnosed and on treatment but not meeting treatment targets, and (iv) diagnosed, on treatment and meeting treatment targets. The total height of the bars represents the prevalence of hypercholesterolaemia in individuals with diabetes.
b No information on current use of cholesterol-lowering medication was available for Colombia. The bars reflect whether individuals are diagnosed and whether they are meeting treatment targets. 
